Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma.
Katodritou E, Terpos E, Zervas K, Speletas M, Kapetanos D, Kartsios C, Verrou E, Banti A, Effraimidou S, Christakis J. Katodritou E, et al. Among authors: zervas k. Ann Hematol. 2007 May;86(5):369-76. doi: 10.1007/s00277-007-0258-x. Epub 2007 Feb 14. Ann Hematol. 2007. PMID: 17375302 Clinical Trial.
Sequential evaluation of serum hepcidin in anemic myeloma patients: study of correlations with myeloma treatment, disease variables, and anemia response.
Katodritou E, Ganz T, Terpos E, Verrou E, Olbina G, Gastari V, Hadjiaggelidou C, Varthaliti M, Georgiadou S, Westerman M, Zervas K. Katodritou E, et al. Among authors: zervas k. Am J Hematol. 2009 Aug;84(8):524-6. doi: 10.1002/ajh.21448. Am J Hematol. 2009. PMID: 19536845 Free article. No abstract available.
Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
Katodritou E, Terpos E, North J, Kottaridis P, Verrou E, Gastari V, Chadjiaggelidou C, Sivakumaran S, Jide-Banwo S, Tsirogianni M, Kapetanos D, Zervas K, Lowdell MW. Katodritou E, et al. Among authors: zervas k. Am J Hematol. 2011 Dec;86(12):967-73. doi: 10.1002/ajh.22163. Epub 2011 Sep 14. Am J Hematol. 2011. PMID: 21919039 Free article.
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
Katodritou E, Terpos E, Symeonidis AS, Pouli A, Kelaidi C, Kyrtsonis MC, Kotsopoulou M, Delimpasi S, Christoforidou A, Giannakoulas N, Viniou NA, Stefanoudaki E, Hadjiaggelidou C, Christoulas D, Verrou E, Gastari V, Papadaki S, Polychronidou G, Papadopoulou A, Giannopoulou E, Kastritis E, Kouraklis A, Konstantinidou P, Anagnostopoulos A, Zervas K, Dimopoulos MA. Katodritou E, et al. Among authors: zervas k. Am J Hematol. 2014 Aug;89(8):803-8. doi: 10.1002/ajh.23745. Epub 2014 May 12. Am J Hematol. 2014. PMID: 24757085 Free article.
The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group.
Terpos E, Christoulas D, Kastritis E, Katodritou E, Papatheodorou A, Pouli A, Kyrtsonis MC, Michalis E, Papanikolaou X, Gkotzamanidou M, Koulieris E, Gavriatopoulou M, Zervas K, Dimopoulos MA; Greek Myeloma Study Group. Terpos E, et al. Among authors: zervas k. Am J Hematol. 2014 Jan;89(1):34-40. doi: 10.1002/ajh.23577. Am J Hematol. 2014. PMID: 23983166 Free article.
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.
Terpos E, Katodritou E, Tsiftsakis E, Kastritis E, Christoulas D, Pouli A, Michalis E, Verrou E, Anargyrou K, Tsionos K, Dimopoulos MA, Zervas K; Greek Myeloma Study Group. Terpos E, et al. Among authors: zervas k. Haematologica. 2009 Mar;94(3):372-9. doi: 10.3324/haematol.2008.000638. Haematologica. 2009. PMID: 19252175 Free PMC article. Clinical Trial.
70 results